Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor co-agonist, has demonstrated significant efficacy in the management of obesity and type 2 diabetes. However, its use can be associated with severe gastrointestinal (GI)-related adverse effects. This case report describes a 38-year-old male who developed severe vomiting and